Xylitol × Cardiovascular Risk
Does high xylitol intake double the risk of heart attack and stroke?
Blood xylitol was measured. Xylitol intake wasn't.
Higher fasting blood xylitol was associated with greater cardiovascular risk, and experimental work found increased platelet reactivity. But dietary xylitol intake was not measured, the primary adjusted association was about 57% higher rather than double, and the observational data do not establish that consuming xylitol causes heart attacks or strokes.
“High intake of xylitol doubles the risk of heart attack and stroke.”
ORIGINAL CLAIM SOURCEX · @cnn_co_jp · 18 OCT 2026VIEW ORIGINAL POSTWhat the evidence says
CITATION
Witkowski et al. (2024) · European Heart Journal · DOI 10.1093/eurheartj/ehae244
DESIGN
Discovery cohort n=1,157 + validation cohort n=2,149 · fasting plasma xylitol · 3-year MACE follow-up
MECHANISTIC WORK
Mechanistic experiments + acute 30 g xylitol challenge in 10 healthy volunteers
- In the validation cohort, people in the highest versus lowest fasting-plasma xylitol tertile had greater three-year risk of major adverse cardiovascular events; the adjusted hazard ratio was 1.57 (95% CI 1.12–2.21).
- Laboratory experiments found xylitol increased platelet responsiveness, and a mouse arterial-injury model showed enhanced thrombosis potential.
- In a small acute feeding experiment, 30 g of xylitol caused a large short-lived rise in plasma xylitol and increased measures of platelet responsiveness.
- The human cohorts measured overnight-fasting plasma xylitol. They did not measure dietary xylitol intake, and the authors explicitly reported that dietary information was unavailable.
- The primary adjusted association was about 57% higher relative risk, not a demonstrated doubling of risk caused by xylitol consumption.
- The cohort endpoint was a composite of death, myocardial infarction and stroke. The headline reduces that composite to heart attack and stroke.
- The cohort evidence is observational. Xylitol is also produced endogenously, so fasting blood levels cannot be treated as a direct measure of habitual xylitol consumption or proof of causation.
The study identified a credible cardiovascular signal that deserves further investigation. Higher fasting plasma xylitol tracked with higher MACE risk, and experimental work provides a plausible platelet and thrombosis mechanism.
But the headline crosses an evidentiary boundary: fasting blood xylitol is not the same thing as measured dietary intake. The study cannot establish that consuming more xylitol caused the observed cardiovascular events.
A 2025 methodological critique argued endogenous xylitol could contribute to the association; the study authors responded that adjustment and mechanistic evidence support biological plausibility. That remains an active scientific question rather than a settled causal conclusion.